Maya Ramirez has attended diabetes camps her entire life. Her first trip to an adult diabetes camp helped her process the ...

Qatar Foundation member Sidra Medicine has conducted the industry-sponsored ‘sunRIZE’ trial for paediatric congenital hyperinsulinism. The first pharmaceutical trial comes after Sidra launched ...

This would be regarding the use of ersodetug in the ongoing phase 3 sunRIZE study targeting patients with Congenital Hyperinsulinism [cHI]. The reason investors should care about this trial before ...

Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market. For the second time ...

Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar's first industry-sponsored pharmaceutical trial for pediatric congenital hyperinsulinism on a young patient.

These forward-looking statements include but are not limited to statements regarding the ersodetug Expanded Access Program, the ability of ersodetug to become an effective treatment for congenital ...

(Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced the U.

Doha, Qatar: Sidra Medicine, a member of Qatar Foundation, has successfully conducted Qatar's first industry-sponsored pharmaceutical trial for pediatric congenital hyperinsulinism on a young patient.